KKR closed its $5.89 billion acquisition of Integer Holdings on schedule, finalizing the largest healthcare private equity transaction in a month when global PE dealmaking otherwise contracted. The medical-device manufacturer, which supplies components for cardiac rhythm management and neuromodulation systems, moved off public markets without extension or renegotiation. KKR paid the agreed price.
August private equity volume fell across most sectors. Healthcare absorbed a disproportionate share of the capital that did move, with Integer representing nearly half the month's sector total by disclosed value. The takeout removes a $5.8 billion market-cap company that was trading below its five-year average multiple before KKR's approach in May. Integer's revenue run rate at close: $1.47 billion, with 78% derived from original equipment manufacturer contracts with the ten largest medical-device companies. The customer concentration is the asset—KKR bought embedded supplier relationships, not a brand.
The deal structure matters for where healthcare PE is headed. KKR is taking Integer private at a moment when public medical-device multiples compress under rate pressure, but private credit remains available for stable cash-flow assets with recurring revenue. Integer's EBITDA margins held at 22% through the bid period, supported by long-term supply agreements that behave like subscriptions. That profile—high margins, low customer churn, minimal end-market exposure—is now the only healthcare profile attracting $5 billion-plus checks in this rate environment.
The timing also marks a shift in what KKR will do with operational healthcare assets. The firm has been rotating out of provider-services plays and into manufacturing and medical technology, where margin compression is slower and reimbursement risk is indirect. Integer's portfolio includes programmable batteries, enclosures, and lead systems that are specified into devices years before launch. KKR inherits a three-to-five-year forward order book with price escalators. The model is manufacturing discipline applied to medical tech, not growth-stage bets on procedure volume.
Allocators should watch KKR's post-close capital deployment into Integer's neuromodulation segment, which has been underinvested relative to cardiac. Management flagged $120 million in deferred capex during the sale process. If KKR funds that build-out in the next twelve months, it signals confidence that neuromodulation reimbursement will stabilize ahead of the 2025 device-refresh cycle. The firm's healthcare infrastructure fund, which has $15 billion in dry powder, has been quiet since June. Integer may preview the deployment pattern.
Integer's manufacturing footprint is in Mexico, Costa Rica, and the U.S., with 61% of production offshore. KKR now owns the supply-chain risk that every large-cap device company has been trying to diversify. If the firm announces facility expansion in the next six months, particularly U.S.-based clean-room capacity, it will confirm that OEM customers are willing to pay for geographic redundancy. That would be the healthcare supply-chain tell for 2024.